Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs ...
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funding to advance a HER2-targeted, dual ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
(PDCs) demonstrate tumor-selective delivery and potent anticancer activityPreclinical data show robust efficacy as ...
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...
Oqory’s planned reverse merger with fellow antibody-drug conjugate (ADC) company Vincerx Pharma has fallen apart at the last ...
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17).
News Medical on MSN6d
Novel cancer treatment uses bacterial toxin to train immune systemResearchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback